Advancing Prostate Cancer Treatment: Innovations and Challenges in Immunotherapy

Area of Science:

• Oncology
• Immunology

Background:

• Prostate cancer (PCa) remains a significant cause of cancer mortality in men.
• The advent of immunotherapy has initiated a paradigm shift in PCa treatment strategies.

Purpose of the Study:

• To examine the immunological landscape of prostate cancer.
• To highlight current and emerging immunotherapeutic approaches for PCa.
• To address challenges and explore combination strategies for enhanced efficacy.

Main Methods:

• Review of key immunotherapeutic strategies including cancer vaccines, immune checkpoint inhibitors (ICIs), adoptive cell therapies, and cytokine-based treatments.
• Examination of novel innovations such as oncolytic viruses, neoantigen-based therapies, and bispecific antibodies.
• Discussion of challenges including the immunosuppressive tumor microenvironment (TME), biomarker limitations, and immune-related adverse events (irAEs).

Main Results:

• Immunotherapy offers a promising frontier for prostate cancer treatment.
• Combination strategies involving androgen deprivation therapy (ADT), radiotherapy, and targeted therapies show potential.
• Advances in biomarker discovery and artificial intelligence (AI) are crucial for personalized immunotherapy.

Conclusions:

• Integrating immunotherapy into standard prostate cancer care is essential for transformative patient outcomes.
• Equitable access to advanced immunotherapies must be prioritized.
• Future directions focus on optimizing personalized treatment through biomarker and AI advancements.